I was just a baby scientist when I discovered the hormone that made Ozempic possible. I had no idea how life-changing—and ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile ...

Disease-modifying treatments for major neurocognitive disorders, including Alzheimer’s disease, Parkinson’s disease and other cognitive deficits, are among the main unmet needs in modern medicine.

Glucagon-like peptide-1 receptor agonists (GLP1RAs) are used to treat diabetes, obesity, and polycystic ovarian syndrome (PCOS) Semaglutide, liraglutide, lixisenatide, dulaglutide, and tirzepatide are ...

Some preclinical studies and human case reports have found glucagon-like peptide-1 receptor (GLP-1) agonists reduced alcohol consumption, though they are only approved for diabetes and obesity ...

Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: A clinical perspective Peer-Reviewed Publication Xia & He Publishing Inc.

These drugs mimic the action of a naturally occurring hormone, glucagon-like peptide (GLP -1), and for decades have been used to treat diabetes. More recently they have become a wildly popular way ...

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists ...

However, the current understanding of glucagon-like peptide-1 actions in renal pathways is inadequate. In rodent and human kidneys, GLP-1 receptors are present in vascular smooth muscles rather ...

Glucagon-like peptide-1 (GLP-1) is a member of the incretin family of peptide hormones secreted by intestinal enteroendocrine L-cells. GLP-1 induces the release of insulin from beta cells in a glucose ...